Paris, October 17, 2016

Transcription

1 An Unique Collection of Human Primary Lymphoid Cells for In vitro Preclinical Tests Thierry Fest, Laboratory Microenvironment & Cancer, Rennes University Hospital Paris, October 17, 2016

2 CeVi_Collection: a Collaborative Project CeVi_collection: A collection of human viable cells perfectly annotated corresponding to cell suspensions issued from lymphoma tumors and reactive lymphoid tissues Biological materials Tumor, Blood, Bone Marrow Cryopreserved in DMSO Derived nucleic acids: DNA/RNA Plasma A network of 6 standardized CALYM platforms Belong to university hospitals Backed by Biological Resource Centers Enriched collection Clinical information State-of-art histopathological diagnosis including IHC results Immunophenotyping with a dedicated flow cytometry panel 2

3 CeVi_Collection: Overview 3 years 600 patients, 780 samples over 3200 vials Broad variety of lymphoma entities Reactive Others DLBCL Distribution according tissue origin Blood Marrow MZL MCL Follicular Lymphoma Lymph node Spleen Others PTCL Other B cell lymphoma Hodgkin 3

4 A Tool for Partnership 3 executed contracts British, American and Swiss companies 3 contracts in progress First prospective projects A strong expertise Adaptive: Ad-hoc collections for specific projects Initiative: Scientific proposals, Call for projects, 3 internal projects Example: CeVi-Hodgkin project

5 Testing Phagocytosis for a New Humanized Monoclonal Ab on Primary Lymphoma Cells Produc on of human monocyte-derived macrophages for subsequent cultures Healthy donor Buffy Coat Indirect magnetic labelling of non-monocytes using a cocktail of biotinylated antibodies and Anti-biotin Microbeads Peripheral Blood Mononuclear cells Non-monocytes are retained in a MACS Column placed in a MACS Separator, Monocytes pass through the colmn and are collected as the enrched, unlabeled cell fraction 7 days of M-CSF culture + 3 days of M-CSF + IL4 + IL10 culture à Differenciated Monocyte-derived Macrophage Cells (MDM) à Each sample was genotyped for FCGR3a-V176F polymorphism (VV, FF or VF), polymorphism being associated with differential affinity of the receptor for mab

6 High Skills and Adaptive Offer Depending of the Industrial Request An body dependent cellular phagocytosis (ADCP) assay se ng up Macrophage Cells CFSE Staining Lymphoma cell line SUDHL4 1- phrodo Red Staining (= ph indicator) phrodo principle 2- Antibody-coating Tumor cells (expl Rituximab, mab) Coculture during 2h at 37 c Monitoring of ADCP events by microscopy CFSE phrodo Bright Field Merge (CFSE+pHrodo)

7 Conditioning CeVi Samples Before Experiments Thawed Lymph Node dissociated cells N=10, Follicular Lymphoma samples N=10, Diffuse Large B Cell Lymphoma samples Indirect magnetic labelling of non-b cells using a cocktail of biotinylated antibodies and Anti-biotin Microbeads Purified B cells 1- phrodo Red Labelling (= ph indicator) 2- Antibody-coating Tumor cells (expl Rituximab, mab) ADCP assay

8 Hodgkin Project Immunophenotypic and molecular characterization of myeloid and lymphoid compartments Assessment of functional interactions between tumor cells and their microenvironment; functional impact of targeted therapy Brentuximab vedotin and/or PD1 inhibitors This work provides a rational for future therapeutic trials whose aim will be to control the recruitment of tumor supportive cells or blockage of their suppressive functions.

9 Microenvironnement in Hodgkin s Lymphoma Innovative high definition technologies to extensively characterize microenvironment populations - Single-cell approaches - Multicolor flow - Multicolor confocal Specific focus on Myeloid populations by tracking their immunosuppressive activity - MDSC characterization - Immuno-active secreted soluble factors Functional interactions - Coculture - Expression of cytokines and immunosuppressive enzymes - On and post-therapy immunomonitoring Focus on Cytotoxic T cell populations and their functionality - Assessment T cell responses - Exhausted T cell subset Only feasible with a relevant viable sample collection IN-VITRO PARTNERING PERSPECTIVE Specific technology developed will be used to characterize in-vitro the effect of drugs on the HRSmicroenvironment interaction. Particularly relevant for checkpoint inhibitors and CD30 therapeutics. TRANSLATIONAL PARTNERING PERSPECTIVE Identified markers and ex-vivo functional assays may be derived into liquid biopsies assays or standardized clinical-grade assays to monitor the effect of drugs on refractory disease.

10 Thierry FEST Céline PANGAULT Roch HOUOT Mikael ROUSSEL Vanessa THOUAULT Emeline Mollaret Gilles UZÉ Caroline BRET Guillaume CARTRON Jérôme MOREAUX Ouissem KARMOUS-GADACHA Pierre BROUSSET Camille LAURENT Loïc YSEBAERT Pauline GRAVELLE Gilles SALLES Lucile BASEGGIO Clémentine SARKOZY Hélène VARNIER Thanks to all the teams, pathologists, biologists, clinicians... involved Daniel OLIVE / Bertrand NADEL Emilie MAMESSIER Florence BROUSSAIS Thibault SACHE Philippe GAULARD Flavia CASTELLANO Jehan DUPUIS/Corinne HAIOUN Aurélie DUPONT Eric SOLARY Valérie CAMARA-CLAYETTE Vincent RIBRAG Véronique VERGÉ Mahmoud KEFFOUS 10